Novilytic Joins California Life Sciences

WEST LAFAYETTE, Ind. – Novilytic, an innovator in molecular recognition technology, is proud to announce that it has joined the California Life Sciences (CLS).

CLS is California’s premier advocacy and industry association, dedicated to advancing life sciences innovation and partnerships. While its focus is on the state of California, the organization has members from all 50 states and an international presence.

Novilytic’s membership signifies a further commitment to a deeper, more involved presence in the overall West Coast life sciences ecosystem. As members, they will have access to CLS’s extensive network, industry events, advocacy initiatives, and collaborative forums designed to accelerate scientific advances.

“Joining the California Life Sciences aligns with our goals of further integration and partnership within the broader life sciences community, especially our valued California customers and prospects,” said Paul Dreier, CEO of Novilytic. “We look forward to collaborating with peers who share our dedication to advancing technologies that simplify bioanalysis."

Headquartered in West Lafayette, Indiana, Novilytic has a presence throughout North America and Europe. Their Proteometer® platform comprises three products that enable upstream pharmaceutical development teams to eliminate sample preparation, cut costs, reduce time-to-market, and streamline analytical workflows. They plan to release at least two new versions of the Proteometer in 2026.

About CLS

California Life Sciences (CLS) is the leading life sciences membership organization in California, dedicated to advancing public policy, fostering innovation, and improving access to transformative technologies across the biotechnology, pharmaceutical, medical device, and diagnostics sectors. For more than 30 years, CLS has supported organizations of all sizes and continues to grow California’s life sciences ecosystem and global impact.

About Novilytic

Novilytic simplifies bioanalysis research for protein-based pharmaceuticals. Their Proteometer product line is revolutionizing drug development and clone selection by eliminating sample preparation steps that were previously industry-standard. Their transformational technology fundamentally improves the analysis of antibodies and other biopharmaceuticals by enabling near-real-time molecular-structure analysis. This reduces the time and cost of drug development, ultimately helping to bring lifesaving treatments to the market faster. For more information, visit Novilytic.com.

Media Inquiries: Ryan Simpson, Director of Marketing, Novilytic, rsimpson@novilytic.com

###